{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:02:56Z","timestamp":1789642976017,"version":"4.0.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["2025090"],"award-info":[{"award-number":["2025090"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel cell and gene therapies hold great potential to alter the clinical course of a range of chronic diseases, yet uncertainties remain regarding their long-term efficacy and impact. These uncertainties pose challenges for Health Technology Assessment (HTA) committees, which systematically assess health interventions seeking public subsidy. Haematological conditions are a common target for gene therapies; however, the perspectives of those both directly and indirectly impacted by funding decisions for therapies in this disease area have not been investigated. To support future HTA considerations of gene therapies, we explored the perspectives of individuals living with haematological conditions who may become eligible for such treatments, alongside their caregivers and members of the general population in Australia. We undertook interviews and focus groups with 55 participants with lived experience and 32 general population members to elicit responses on what might influence decision making on gene therapies; the potential benefits or harms of gene therapies; any perceived barriers to gene therapy access; and\/or uncertainties associated with the respective gene therapy. Here, we describe the parallel perspectives of health consumers and the general population, providing five key areas of consideration for HTA decision-making: individual patient and disease factors; geographical, financial and clinical access; balancing disease and quality of life benefits with adverse effects; individual and health system costs; and remaining treatment uncertainties. These will require resolution before widespread acceptability and uptake of gene therapy.<\/jats:p>","DOI":"10.1038\/s41434-026-00643-z","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:22:08Z","timestamp":1789640528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient, consumer and societal values, perceptions and preferences on high-cost gene therapies"],"prefix":"10.1038","author":[{"given":"Amanda","family":"Rush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De Abreu Lourenco","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippy","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"643_CR1","doi-asserted-by":"crossref","unstructured":"Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359.","DOI":"10.1126\/science.aan4672"},{"key":"643_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.vhri.2020.09.001","volume":"24","author":"H Kim","year":"2021","unstructured":"Kim H, Byrnes J, Goodall S. ISPOR Australia Chapter executive committee. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee. Value Health Reg Issues. 2021;24:6\u201311.","journal-title":"Value Health Reg Issues"},{"key":"643_CR3","doi-asserted-by":"crossref","unstructured":"Gicquel T, Cortial L, Lutsyk K, Forget S, Braun S, Boyer P-O, et al. 2017-2023: State of the art of gene therapies in rare diseases in Europe: the dynamics of clinical R&D, new approved treatments and expected therapies in the pipeline. Rare Dis Orphan Drugs J. 2023;2.","DOI":"10.20517\/rdodj.2023.29"},{"key":"643_CR4","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10198-020-01212-w","volume":"21","author":"D Coyle","year":"2020","unstructured":"Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg JM, Greiner W, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ. 2020;21:1421\u201337.","journal-title":"Eur J Health Econ"},{"key":"643_CR5","unstructured":"Nathan-Kazis J FDA Approves Bluebird Bio\u2019s Pricey Gene Therapy. 2022 [Available from: https:\/\/www.barrons.com\/articles\/fda-approves-pricey-gene-therapy-51660765753] Accessed 20th August 2026."},{"key":"643_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41434-023-00402-4","volume":"30","author":"KN Vokinger","year":"2023","unstructured":"Vokinger KN, Glaus CEG, Kesselheim AS. Approval and therapeutic value of gene therapies in the US and Europe. Gene Ther. 2023;30:756\u201360.","journal-title":"Gene Ther"},{"key":"643_CR7","doi-asserted-by":"crossref","unstructured":"Editorial. The gene-therapy revolution risks stalling if we don\u2019t talk about drug pricing. Nature. 2023;616:629\u201330.","DOI":"10.1038\/d41586-023-01389-z"},{"key":"643_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/03007995.2023.2257600","volume":"39","author":"P Buedo","year":"2023","unstructured":"Buedo P, Bianchini A, Klas K, Waligora M. Bioethics of somatic gene therapy: what do we know so far? Curr Med Res Opin. 2023;39:1355\u201365.","journal-title":"Curr Med Res Opin"},{"key":"643_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09494-5","volume":"23","author":"M Drummond","year":"2023","unstructured":"Drummond M, Ciani O, Fornaro G, Jommi C, Dietrich ES, Espin J, et al. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? BMC Health Serv Res. 2023;23:484.","journal-title":"BMC Health Serv Res"},{"key":"643_CR10","unstructured":"Australian Government. The Pharmaceutical Benefits Scheme 2026 2026 [Available from: https:\/\/www.pbs.gov.au\/pbs\/home] Accessed 20th August 2026."},{"key":"643_CR11","unstructured":"Australian Government. Medical Services Advisory Committee applications 2026 [Available from: https:\/\/www.msac.gov.au\/applications]. Accessed 20th August 2026."},{"key":"643_CR12","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s12325-017-0587-7","volume":"34","author":"H Strong","year":"2017","unstructured":"Strong H, Mitchell MJ, Goldstein-Leever A, Shook L, Malik P, Crosby LE. Patient perspectives on gene transfer therapy for sickle cell disease. Adv Ther. 2017;34:2007\u201321.","journal-title":"Adv Ther"},{"key":"643_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/hae.14188","volume":"27","author":"K Khair","year":"2021","unstructured":"Khair K, Steadman L, Chaplin S, Holland M, Jenner K, Fletcher S. Parental perspectives on gene therapy for children with haemophilia: The Exigency study. Haemophilia. 2021;27:120\u20138.","journal-title":"Haemophilia"},{"key":"643_CR14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41436-018-0409-6","volume":"21","author":"A Persaud","year":"2019","unstructured":"Persaud A, Desine S, Blizinsky K, Bonham VL. A CRISPR focus on attitudes and beliefs toward somatic genome editing from stakeholders within the sickle cell disease community. Genet Med. 2019;21:1726\u201334.","journal-title":"Genet Med"},{"key":"643_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"643_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377\u201381.","journal-title":"J Biomed Inf"},{"key":"643_CR17","unstructured":"Lumivero. NVivo (Version 14). 14 ed. 2023."},{"key":"643_CR18","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V Thematic Analysis: A practical guide: Sage Publication; 2021.","DOI":"10.4135\/9781036232078.n9"},{"key":"643_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277\u201388.","journal-title":"Qual Health Res"},{"key":"643_CR20","first-page":"315","volume":"6","author":"AM Fontrier","year":"2022","unstructured":"Fontrier AM, Visintin E, Kanavos P. Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries. Pharm Open. 2022;6:315\u201328.","journal-title":"Pharm Open"},{"key":"643_CR21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/hae.14378","volume":"27","author":"S Fletcher","year":"2021","unstructured":"Fletcher S, Jenner K, Holland M, Chaplin S, Khair K. An exploration of why men with severe haemophilia might not want gene therapy: The exigency study. Haemophilia. 2021;27:760\u20138.","journal-title":"Haemophilia"},{"key":"643_CR22","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.2147\/PPA.S355627","volume":"16","author":"M Wang","year":"2022","unstructured":"Wang M, Negrier C, Driessler F, Goodman C, Skinner MW. The hemophilia gene therapy patient journey: questions and answers for shared decision-making. Patient Prefer Adherence. 2022;16:1439\u201347.","journal-title":"Patient Prefer Adherence"},{"key":"643_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40271-019-00395-6","volume":"13","author":"EC van Balen","year":"2020","unstructured":"van Balen EC, Wesselo ML, Baker BL, Westerman MJ, Coppens M, Smit C, et al. Patient perspectives on novel treatments in haemophilia: a qualitative study. Patient. 2020;13:201\u201310.","journal-title":"Patient"},{"key":"643_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102237","volume":"7","author":"L Baas","year":"2023","unstructured":"Baas L, Meijer K, Driessens M, Bredenoord AL, van der Graaf R. SYMPHONY consortium. Ethical aspects of hemophilia gene therapy: a qualitative interview study with stakeholders. Res Pr Thromb Haemost. 2023;7:102237.","journal-title":"Res Pr Thromb Haemost"},{"key":"643_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s12519-022-00675-6","volume":"19","author":"S Teutsch","year":"2023","unstructured":"Teutsch S, Zurynski Y, Eslick GD, Deverell M, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: health service use and barriers to accessing care. World J Pediatr. 2023;19:701\u20139.","journal-title":"World J Pediatr"},{"key":"643_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02256-2","volume":"17","author":"S Fletcher","year":"2022","unstructured":"Fletcher S, Jenner K, Pembroke L, Holland M, Khair K. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet J Rare Dis. 2022;17:155.","journal-title":"Orphanet J Rare Dis"},{"key":"643_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12887-022-03598-3","volume":"22","author":"MO Quarmyne","year":"2022","unstructured":"Quarmyne MO, Ross D, Sinha C, Bakshi N, Boudreaux J, Krishnamurti L. Decision-making about gene therapy in transfusion dependent thalassemia. BMC Pediatr. 2022;22:536.","journal-title":"BMC Pediatr"},{"key":"643_CR28","doi-asserted-by":"publisher","first-page":"e0315381","DOI":"10.1371\/journal.pone.0315381","volume":"20","author":"A Baghbanian","year":"2025","unstructured":"Baghbanian A, Carter D, Merlin T. Methods for the health technology assessment of complex interventions: A scoping review. PLoS One. 2025;20:e0315381.","journal-title":"PLoS One"},{"key":"643_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03068-2","volume":"19","author":"S Fletcher","year":"2024","unstructured":"Fletcher S, Jenner K, Holland M, Khair K. Barriers to gene therapy, understanding the concerns people with haemophilia have: an exigency sub-study. Orphanet J Rare Dis. 2024;19:59.","journal-title":"Orphanet J Rare Dis"},{"key":"643_CR30","unstructured":"NSW Government. IPTASS (Isolated Patients Travel and Accommodation Assitance Scheme 2025 [01\/05\/25]. Available from: https:\/\/www.iptaas.health.nsw.gov.au\/ Accessed 20th August 2026."},{"key":"643_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s40271-020-00442-7","volume":"13","author":"TC Vasquez-Loarte","year":"2020","unstructured":"Vasquez-Loarte TC, Lucas TL, Harris-Wai J, Bowen DJ. Beliefs and values about gene therapy and in-utero gene editing in patients with hemophilia and their relatives. Patient. 2020;13:633\u201342.","journal-title":"Patient"},{"key":"643_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/PPA.S406894","volume":"17","author":"J Limjoco","year":"2023","unstructured":"Limjoco J, Thornburg CD. Gene therapy for hemophilia A: A mixed methods study of patient preferences and shared decision-making. Patient Prefer Adherence. 2023;17:1093\u2013105.","journal-title":"Patient Prefer Adherence"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00643-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00643-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00643-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:22:13Z","timestamp":1789640533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00643-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00643-z","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A\/Professor KM is a member of the Pharmaceutical Benefits Advisory Committee and a member of the Economics Sub Committee of the Pharmaceutical Benefits Advisory Committee. Professor KH is a member of the Pharmaceutical Benefits Advisory Committee and Chair of the Economics Sub Committee of the Pharmaceutical Benefits Advisory Committee. Professor RV is a member of the Life Saving Drugs Programme Expert Panel. Adjunct Associate Professor Jo Watson is Deputy Chair of the Pharmaceutical Benefits Advisory Committee and a member of the Economics Sub Committee of the Pharmaceutical Benefits Advisory Committee.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by The University of Sydney Human Research Ethics Committee (approval number 2024\/HE000224). All participants provided informed consent.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}